Literature DB >> 3335690

Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy.

W J McKenna1, R C Franklin, P Nihoyannopoulos, K C Robinson, J E Deanfield.   

Abstract

In adults with hypertrophic cardiomyopathy, the annual mortality rate from sudden death is 2 to 3%, and the finding of nonsustained ventricular tachycardia during electrocardiographic (ECG) monitoring provides a marker of the patient who is at increased risk. In the young, the annual mortality rate from sudden death is even higher, approximately 6%, but the prognostic significance of arrhythmia is unknown. To determine the prevalence of arrhythmia and its relation to prognosis, 2 days of ECG monitoring was performed in 6 infants, 14 children and 33 adolescents with hypertrophic cardiomyopathy receiving no cardioactive medications. An additional 1 to 9 days (median 2) of monitoring was performed in 29 patients. All patients had sinus rhythm; 4 adolescents had episodes of paroxysmal supraventricular tachycardia, a child with the Wolff-Parkinson-White syndrome had symptomatic reentrant atrioventricular tachycardia and 5 adolescents had asymptomatic nonsustained ventricular tachycardia. During follow-up of 1 week to 7 years (median 3 years), five patients died suddenly and two had successful resuscitation from out-of-hospital ventricular fibrillation; none of these seven patients had ventricular arrhythmias during 2 to 7 days (median 3) of ECG monitoring. The two patients with ventricular fibrillation, the five with ventricular tachycardia, the one with Wolff-Parkinson-White syndrome and the seven with recurrent syncope or adverse family history, or both, received low dose amiodarone. None of these "high risk" patients died during 6 months to 6 years (median 3 years) of follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1988        PMID: 3335690     DOI: 10.1016/0735-1097(88)90181-7

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  28 in total

Review 1.  Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death.

Authors:  William J McKenna; Elijah R Behr
Journal:  Heart       Date:  2002-02       Impact factor: 5.994

2.  Heart rate variability in children with hypertrophic cardiomyopathy.

Authors:  G Butera; D Bonnet; J Kachaner; D Sidi; E Villain
Journal:  Heart       Date:  2003-02       Impact factor: 5.994

Review 3.  Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy.

Authors:  Michael P Frenneaux
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

Review 4.  Hypertrophic cardiomyopathy in childhood.

Authors:  Steven D Colan
Journal:  Heart Fail Clin       Date:  2010-10       Impact factor: 3.179

Review 5.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 6.  Problems in diagnosis and management of hypertrophic cardiomyopathy.

Authors:  O Odemuyiwa; W J McKenna
Journal:  Postgrad Med J       Date:  1991-08       Impact factor: 2.401

7.  Heart rate variability is a weak predictor of sudden death in children and young patients with hypertrophic cardiomyopathy.

Authors:  G Limongelli; T Miele; G Pacileo; G Di Salvo; P Calabro'; R Ancona; S Gala; A Rea; M Verrengia; R Calabro'
Journal:  Heart       Date:  2007-01       Impact factor: 5.994

8.  Genetic testing for familial hypertrophic cardiomyopathy in newborn infants.

Authors:  M P Ryan; J French; S al-Mahdawi; P Nihoyannopoulos; J G Cleland; C M Oakley; P S Harper; A Clarke; J Davis; L Grigg
Journal:  BMJ       Date:  1995-04-01

Review 9.  Management of hypertrophic cardiomyopathy in children.

Authors:  Hubert Seggewiss; Angelos Rigopoulos
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Cardiac dysrhythmias in children with idiopathic dilated or hypertrophic cardiomyopathy.

Authors:  G Müller; H E Ulmer; K J Hagel; D Wolf
Journal:  Pediatr Cardiol       Date:  1995 Mar-Apr       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.